Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer

• Published in: Journal of clinical oncology Vol. 5; no. 10; p. 1566
• Main Authors: Sitzmann, J V, Order, S E, Klein, J L, Leichner, P K, Fishman, E K, Smith, G W
• Format: Journal Article
• Language: English
• Published: United States 01.10.1987
• Subjects: alpha-Fetoproteins - analysis; Antibodies, Monoclonal - therapeutic use; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - surgery; Carcinoma, Hepatocellular - therapy; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms - pathology; Liver Neoplasms - surgery; Liver Neoplasms - therapy; Male; Quality of Life; Radiotherapy - methods; Tomography, X-Ray Computed
• ISSN: 0732-183X
• DOI: 10.1200/JCO.1987.5.10.1566

Eleven patients with hepatocellular cancer had nonresectable lesions, ten as determined by laparotomy and one by computed tomographic (CT) evidence of inferior vena caval invasion. These patients were treated with a variety of new modalities, particularly radiolabeled antiferritin antibodies. Following treatment, seven of the 11 patients were considered to have converted their lesions to possible resectability. Six patients had complete resections, and one patient was partially resected. All patients had the common features of either nodular massive or nodular multifocal hepatocellular cancer. Relative to the patient's initial status, the quality of life remains high, and a new approach in the treatment of the nodular form of nonresectable hepatoma has been demonstrated. The present rate of such conversion to resectability is unknown. However, with further advances in radiolabeled antibody therapy, these results offer a new opportunity in the management of hepatocellular cancer.